KATRD International Conference 2021

Program in Detail

Oral Presentation 16 Lung Cancer 1			10:30-12:00 Jade
Chair	Ji Woong Son (Konyang University, Korea)
10:30-10:40	OP 16-1	microRNA-26a-5p Regulates the Cancer stemness and Enhances the Chemosensitivity of Lung Adenocarcinoma Minhyeok Lee (Konyang University, Korea)
10:40-10:50	OP 16-2	Heterogeneous Radiological Response to Chemotherapy is Associated with Poor Prognosis in Advanced Non-small-cell Lung Cancer Woo Kyung Ryu (Inha University, Korea)
10:50-11:00	OP 16-3	Clinical Significance of Advanced Lung Cancer Inflammation Index in Limited Disease Small Cell Lung Cancer Patients Treated with Chemoradiotherapy DONG WON PARK (Hanyang University, Korea)
11:00-11:10	OP 16-4	Impaired Lung Function and Lung Cancer Incidence: A Nationwide Population-based Cohort Study Hye Seon Kang (The Catholic University of Korea, Korea)
11:10-11:20	OP 16-5	Blood-based Biomarker Analysis for Predicting Efficacy of Definitive Concurrent Chemoradiotherapy and Durvalumab Consolidation in Patients with Unresectable Locally Advanced Non-small Cell Lung Cancer Cheol-Kyu Park (Chonnam National University, Korea)
11:20-11:30	OP 16-6	Clinical Usefulness of Serum KL-6 Test for Predicting Occurrence and Assessing Severity of Treatment-related Interstitial Lung Disease in Lung Cancer: A Single Center Cohort Study Hwa Kyung Park (Chonnam National University, Korea)
11:30-11:40	OP 16-7	Association between Clinical Parameters and Resectability in Stage III Non-small Cell Lung Cancer Seohyun Kim (The Catholic University of Korea, Korea)
11:40-11:50	OP 16-8	Tri-iodothyronine (T3) as a Prognostic Factor for Patients with Advanced Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors Yoonjoo Kim (Chungnam National University, Korea)
11:50-12:00	OP 16-9	Digital Aging and Mental Health Deteriorations: Risk Mitigation in the Older People with Lung Cancer Disease in Indonesia Lintong Hottua Simbolon (Alumnus University of Lampung, Indonesia)
Oral Presentation 17 Lung Cancer 2			13:30-15:00 Jade
Chair	Hak Ryul Kim (Wonkwang University, Korea)
13:30-13:40	OP 17-1	High Tumor Mutation Burden Predicts Unfavorable Clinical Outcomes in EGFR-mutated Lung Adenocarcinoma Treated with Targeted Therapy Seung Hyeun Lee (Kyung Hee University, Korea)
13:40-13:50	OP 17-2	GDF-15 Levels Predict Efficacy in Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitors Da Hyun Kang (Chungnam National University, Korea)
13:50-14:00	OP 17-3	Differences in Detection Patterns, Characteristics, and Outcomes of Central and Peripheral Lung Cancers in Low-dose CT Screening Yeon Wook Kim (Seoul National University Bundang Hospital, Korea)
14:00-14:10	OP 17-4	Comparison of Clinical Characteristics and Prognosis of Incidentally Detected and Screening Detected Lung Cancers Sungmin Zo (Sungkyunkwan University, Korea)
14:10-14:20	OP 17-5	Incidence and Risk Factors for Brain Metastasis in Patients with Presumed Early-stage Lung Cancer Kangjoon Kim (Yonsei University, Korea)
14:20-14:30	OP 17-6	Association Between Quality of Life Questionnaire at Diagnosis and Survival in Patients with Lung Cancer Yu Jin Hong (The Catholic University of Korea, Korea)
14:30-14:40	OP 17-7	Clinical Factors Associated with Circulating Tumor DNA Detection in Chronic Obstructive Pulmonary Disease Patients with Lung Cancer Sun Hye Shin (Sungkyunkwan University, Korea)
14:40-14:50	OP 17-8	Semi-supervised Deep Learning Extraction for Information of Lung Cancer Staging from Unstructured Reports of PET-CT Interpretation Hyungjun Park (University of Ulsan, Korea)
14:50-15:00	OP 17-9	Machine Learning Classification of Bronchogenic Carcinoma based on Fuzzy Logic Rifaldy Fajar (Yogyakarta State University, Indonesia)
Oral Presentation 18 Lung Cancer 3			15:30-17:00 Jade
Chair	Hyunkyung Lee (Inje University, Korea)
15:30-15:40	OP 18-1	Effects of Developed Chronic Pulmonary Aspergillosis after Lung Cancer Surgery on Mortality and Lung Function Decline Bo-Guen Kim (Sungkyunkwan University, Korea)
15:40-15:50	OP 18-2	Efficacy of Local Radiotherapy or Metastasectomy in Stage IV NSCLC with Single Extrathoracic Metastasis: Evaluation of Nationwide Korean Lung Cancer Populations Jeong Uk Lim (The Catholic University of Korea, Korea)
15:50-16:00	OP 18-3	Predictability of Prior Radiotherapy and Immunotherapy-related Adverse Effects for Outcomes in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy Jeong Uk Lim (The Catholic University of Korea, Korea)
16:00-16:10	OP 18-4	The Role of 6-minute Walk Test and Cardiopulmonary Exercise Test in Early-stage Lung Cancer Patients with Reduced Pulmonary Function Daegeun Lee (Sungkyunkwan University, Korea)
16:10-16:20	OP 18-5	Association of Diagnostic Lung Biopsy on the Risk of Spread Through Air Spaces (STAS) and Its Prognostic Impact in Resected Stage I Non-Small Cell Lung Cancer (NSCLC) Ga Young Lee (Seoul National University Bundang Hospital, Korea)
16:20-16:30	OP 18-6	Comparison of Clinical Stage and Pathologic Stage in Patients with Non-small Cell Lung Cancer Hye Ran Gwon (Yonsei University, Korea)
16:30-16:40	OP 18-7	Real-world Experience on the Use of Durvalumab after Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer Eun Hye Lee (Yonsei University, Korea)
16:40-16:50	OP 18-8	A Propensity-matched Real-world Data Analysis of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer Cheol-Kyu Park (Chonnam National University, Korea)
16:50-17:00	OP 18-9	Stereotactic Body Radiation Therapy in Stage I Non-small Cell Lung Cancer Patients with Peripheral Tumors in Vietnam Luan Pham (108 Military Central Hospital, Vietnam)